ROLE OF ANTI-MULLERIAN HORMONE (AMH) IN ASSESSMENT OF THE POLYCYSTIC OVARY SYNDROME (PCOS) SEVERITY A REVIEW

Introduction:The hormone anti-Mullerian hormone (AMH) is produced by granulosa cells in the ovary and has emerged as a potential biomarker for PCOS. The AMH value increases in proportion to the severity of PCOS thus, serum levels of AMH may be a marker for polycystic ovary syndrome and have a diagnostic role in determining the severity of PCOS. Aim: to determine PCOS severity based on the current available literature of the role of AMH. Methods: PubMed, Medline, Embase, and the Cochrane Library were used to conduct this systematic review. Key terms related to POS severity, as well as AMH as an indicator of POS severity, were used to find related studies published between January 2018 and January 2023. Abstracts from all related articles addressing the role of AMH in POS severity assessment were included and reviewed. Results: Ten articles were included, and serum AMH levels were significantly higher in PCOS cases than in controls in the seven included case-control studies. Other studies discovered that AMH levels were strongly related to both sonographic markers studied and mean ovarian volume. Other studies discovered a significant increase in serum AMH levels in PCOS patients, as well as a statistically significant decrease in AMH levels after PCOS treatment. Conclusion: There is evidence that AMH contributes to the severity of PCOS and plays a critical role in PCOS pathophysiology. More experimental research is needed to better understand the AMH-related pathophysiology of PCOS, which could lead to the development of new treatments for this condition.